Liquid Biopsy Market Size Predicted to Increase at a Positive CAGR | Leading Players: Roche Diagnostics, Bio-Rad Laboratories Inc., Myriad Genetics
The Global Liquid Biopsy Market 2032 Industry Report is a professional and in-depth study on the current state of the Liquid Biopsy Market by QMI. The Liquid Biopsy Market is supposed to demonstrate a considerable growth during the forecast period of 2023-2032. The company profiles of all the key players and brands that are dominating the market have been given in this report. Their moves like product launches, joint ventures, mergers and acquisitions and the respective effect on the sales, import, export, revenue and CAGR values have been studied completely in the report.
A Liquid Biopsy, an alternative to surgical biopsies, uses a small blood sample to help identify tumours. The most effective treatments for a patient can be determined by looking for DNA traces of the cancer in the patient’s blood. Non-small cell lung cancer (NSCLC) is diagnosed using liquid biopsies, which are also used to screen for NSCLC and as a companion diagnostic for other cancers like gastrointestinal, colorectal, breast, prostate, and ovarian cancer.
Download Premium Sample of This Strategic Report: https://www.quincemarketinsights.com/request-sample-59383
Impact Factors of Liquid Biopsy Market:
• The next-generation sequencing for advanced cancer patients using liquid biopsies,
• An increase in the number of cancer patients,
• And a rise in patient preference for minimally invasive therapies are all contributing to the growth of the liquid biopsy market.
Recent Developments of Liquid Biopsy Market:
• Thermo Fisher Scientific Inc. (US) introduced the first NGS-based tests to support input from both DNA and RNA in August 2022. The Ion Torrent Oncomine Myeloid MRD Assays (RUO) provide thorough and incredibly sensitive evaluations of myeloid measurable residual (MDR) in bone marrow and blood samples.
• The therascreen EGFR Plus RGQ PCR Kit, a new in vitro diagnostic test for sensitive EGFR mutation analysis, was introduced by QIAGEN N.V. (Netherlands) in May 2022.
• The Guardant360 Response test, developed by Guardant Health, Inc. (US), was made available in June 2021. It monitors changes in circulating tumour DNA (ctDNA) levels.
• The US FDA granted expanded claims for the cobas EGFR Mutation Test v2 to be used as a companion diagnostic (CDx) for a larger group of therapies to treat non-small cell lung cancer to F. Hoffmann-La Roche Ltd. (Switzerland) in October 2020. (NSCLC).
• In order to offer its Target Selector liquid biopsy assay services to physicians and patients in the network, Biocept, Inc. (US) entered into an agreement with a second California-based independent physician association (IPA) in March 2020.
Segmentations Covered in the Report:
Detailed segmentation by area (country), business, type, and application are included in the Liquid Biopsy market research analysis. The research offers comprehensive details on new products, regional investments, and market investments. The Liquid Biopsy market research report also monitors emerging technologies and trends. The most recent market dynamics, including motivating and inhibiting factors, as well as business news like mergers and acquisitions and investments, are also included in the study. This analysis of current market trends from 2023 to 2032 is provided for each of the sub-segments.
Market Segmentation:
By Cancer Type (Lung, Breast, Colorectal, Prostate),
By Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA),
By Product (Instruments, Assay Kits),
By End User (Reference Laboratory)
Regional Overview:
North America (The US, Canada, and Mexico)
Asia-Pacific (Japan, China, India, South Korea, Indonesia, Australia, Rest of Asia Pacific)
Europe (Germany, UK, Italy, Russia, Spain, The Netherlands France, Rest of Europe)
South America (Brazil, Argentina, Columbia, Rest of South America)
Middle East & Africa (United Arab Emirates, Saudi Arabia, South Africa, Rest of Middle East & Africa)
The Key Players in this Market are: Roche Diagnostics, Bio-Rad Laboratories Inc., Myriad Genetics, Inc., Menarini Silicon Biosystems, Genomic Health, Inc., Thermo Fisher Scientific Inc, Illumina, Inc.
Directly Purchase “Single User License” of Liquid Biopsy Market Growth Report (2023-2032) at: https://www.quincemarketinsights.com/insight/buy-now/liquid-biopsy-market/single_user_license
Reasons for Buying Liquid Biopsy Market Report:
– This report gives a forward-looking prospect of various factors driving or restraining market growth.
– It renders an in-depth analysis for changing competitive dynamics.
– It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.
– It gives a ten-year forecast evaluated on the basis of how the market is predicted to grow.
– It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Liquid Biopsy Market.
– This report helps the readers understand key product segments and their future.
– From 2015 to 2023, All Recent Developments have been covered in this Report.
The Research study can answer the following Key questions:
- What will be the progress rate of the Liquid Biopsy Market for the conjecture period, 2032?
- What are the prominent factors driving the Liquid Biopsy Market across different regions?
- Who are the major vendors dominating the Liquid Biopsy industry and what are their winning strategies?
- What will be the market scope for the estimated period?
- What are the major trends shaping the expansion of the industry in the coming years?
- What are the challenges faced by the Liquid Biopsy Market?
Download TOC From Here: https://www.quincemarketinsights.com/request-toc-59383
Contact us:
Quince Market Insights
US +1 208 405 2835
UK +44 1444 39 0986
APAC +91 706 672 4343
